Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients

  • Kwak, Cheol; 
  • Wu, Tony Tong Lin; 
  • Lee, Hyun Moo; 
  • Wu, Hsi Chin; 
  • Hong, Sung Joon; 
  • 외 8명
Citations

WEB OF SCIENCE

12
Citations

SCOPUS

12

초록

ObjectivesTo evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. MethodsIn this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000mg, once daily) and prednisolone (5mg, twice daily). Patients achieving a prostate-specific antigen decline 50% were considered as responding. ResultsA total of 35 patients (43%) achieved prostate-specific antigen response (95% confidence interval 32-54). The median time to prostate-specific antigen progression was 4.7months (95% confidence interval 3.7-8.3); the median overall survival was 11.8months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21nmol/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725mol/L (baseline) to 0.080mol/L (cycle4). The most common adverse event was bone pain (20%); grade3/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%). ConclusionsA combination of abiraterone acetate and prednisolone appears to be a favorable second-line treatment in Taiwanese and Korean patients with advanced metastatic castration-resistant prostate cancer after failed docetaxel-based chemotherapy.

키워드

abiraterone acetate; docetaxel; metastatic castration-resistant prostate cancer; prednisolone; prostate-specific antigen; SURVIVAL; THERAPY; CYP17
제목
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients
저자
Kwak, Cheol; Wu, Tony Tong Lin; Lee, Hyun Moo; Wu, Hsi Chin; Hong, Sung Joon; Ou, Yen Chuan; Byun, Seok Soo; Rhim, Hyou Young; Kheoh, Thian; Wan, Ying; Yeh, Howard; Yu, Margaret K.; Kim, Choung Soo
DOI
10.1111/iju.12589
발행일
2014-12
유형
Article
저널명
International Journal of Urology
권
21
호
12
페이지
1239 ~ 1244